Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$2.94 - $11.87 $30,870 - $124,634
10,500 New
10,500 $81,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $47.9M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Parallax Volatility Advisers, L.P. Portfolio

Follow Parallax Volatility Advisers, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.